Analysis on the change of gut microbiota and metabolome in lung transplant patientsOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study analyzed how the gut microbiota and metabolome differ in lung transplant patients. Researchers combined 16S amplicon sequencing with untargeted metabolomics of fecal samples. They compared no-transplant patients with lung disease against stable transplant recipients and chronic-rejection recipients. Alpha and beta diversity, LEfSe, KEGG pathway enrichment, and Spearman correlations were used. The aim was to connect microbial and metabolic changes to lung transplantation outcomes through the gut-lung axis.
Who was studied?
The study used 52 fecal samples from 52 end-stage lung disease patients at the Wuxi Lung Transplantation Center in China, collected 2021 to 2022. They formed three groups. The no-transplant group had 20 samples, the event-free stable transplant group had 15, and the chronic rejection group had 17. Rejection cases had survived over six months after transplant. No participant used antimicrobials in the month before enrollment or had active infection. Rejection status was confirmed by a multidisciplinary team and biopsy.
What were the most important findings?
Transplant recipients showed lower gut diversity than no-transplant patients, with significant Simpson and Shannon differences for both transplant groups (p less than 0.05). Two genera, including Enterococcus, dominated the transplant groups. Butyrate-producing and glucose-metabolizing genera declined after transplantation. All-trans retinoic acid fell and the intestinal IgA-production pathway was suppressed, with Enterococcus inversely linked to ATRA. Stable and chronic-rejection groups were remarkably similar, differing mainly in one genus more abundant in the stable group. Diversity did not separate the two transplant outcomes.
What are the greatest implications of this study?
The findings suggest lung transplantation reshapes gut microbiota toward infection-linked genera and away from protective butyrate producers. Reduced ATRA and IgA may weaken mucosal defense and raise infection risk. Because stable and rejection profiles overlapped, gut microbiota did not appear to mark chronic rejection in this cohort. The study is observational, was limited to the genus level, and omitted confounders like age and sex. The authors propose monitoring specific microbes, ATRA, and IgA as candidate targets for improving post-transplant outcomes.